Douglas V. Faller, MD, PhD
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MD, Harvard University
PhD, Massachusetts Institute of Technology




Dr. Douglas Faller is a Boston-based physician/scientist with over 15 years of pharmaceutical and biotech experience involving discovery, pre-clinical and clinical development of small molecules for several therapeutic areas, specializing in oncology and hematology, plus over 25 years of academic clinical and laboratory research experience in the fields of drug discovery and development, oncology and hematology, cell and molecular biology, management of professionals, including the programmatic organization of large groups of scientists, and development of research and drug development programs.

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




Boston University Cross-Disciplinary Training in Nanotechnology for Cancer
09/01/2010 - 07/31/2016 (Multi-PI)
PI: Douglas V. Faller, MD, PhD
NIH/National Cancer Institute
5R25CA153955-05

Targeting N-RAS as a Therapeutic Approach for Melanoma
05/01/2012 - 04/30/2016 (PI)
Melanoma Research Alliance


PKC-Inhibitors as Targeted Therapeutics for Systemic Sclerosis
01/15/2014 - 01/14/2016 (PI)
Scleroderma Foundation


Non-Oncogene Addiction as a Targeted Therapy for Pancreatic Cancer
01/01/2013 - 12/31/2015 (PI)
NIH/National Cancer Institute
5R21CA164245-02

Institutional Research Grant
01/01/2012 - 12/31/2015 (PI of Sub-Project / SP)
PI: Avrum Spira, MD
American Cancer Society - MA Division


Mechanisms of Action and Signaling by Steroid Hormone Antagonists
06/01/2003 - 12/31/2015 (PI)
NIH/National Cancer Institute
5R01CA101992-09

Targeting N-Ras as a Terapeutic Approach to Melanoma
09/30/2012 - 09/29/2014 (PI)
Department of Defense/Army Medical Research Acquisition Activity


Synthetic Lethality as a Targeted Approach to Advanced Prostate Cancer
03/01/2011 - 02/28/2014 (PI)
Department of Defense/Army


Virus-Targeted Therapy for Malignancies
09/26/2011 - 08/31/2012 (Subcontract PI)
Phoenicia Biosciences, Inc. NIH NCI
R43CA153474-01A1

Virus-Targeted Therapeutic for Epstein-Barr Virus-Associated Lymphomas
08/01/2009 - 07/31/2012 (PI)
V Foundation


Showing 10 of 40 results. Show All Results

SWOG - NCI
02/23/2004 - 02/28/2018 (PI)
South West Oncology Group


Title


Yr Title Project-Sub Proj Pubs
2020 Development of a Clinical Hemoglobin Modulator 1R33HL147845-01A1
2014 Non-Oncogene Addiction as a Targeted Therapy for Pancreatic Cancer 5R21CA164245-02 5
2014 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 5R25CA153955-05 44
2014 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 3R25CA153955-05S1 44
2014 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 3R25CA153955-05S2 44
2013 Non-Oncogene Addiction as a Targeted Therapy for Pancreatic Cancer 1R21CA164245-01A1 5
2013 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 5R25CA153955-04 44
2013 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 3R25CA153955-04S1 44
2013 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 3R25CA153955-04S2 44
2013 Mechanisms of Action and Signaling by Steroid Hormone Antagonists 5R01CA101992-09 20
Showing 10 of 90 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020 Sep 11. PMID: 32913286
     
  2. Pearson ADJ, Zwaan CM, Kolb EA, Karres D, Guillot J, Kim SY, Marshall L, Tasian SK, Smith M, Cooper T, Adamson PC, Barry E, Benettaib B, Binlich F, Borgman A, Brivio E, Capdeville R, Delgado D, Faller D, Fogelstrand L, Fraenkel PG, Hasle H, Heenen D, Kaspers G, Kieran M, Klusmann JH, Lesa G, Ligas F, Mappa S, Mohamed H, Moore A, Morris J, Nottage K, Reinhardt D, Scobie N, Simko S, Winkler T, Norga K, Reaman G, Vassal G. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2020 Sep; 136:116-129. PMID: 32688206
     
  3. Moos WH, Faller DV, Glavas IP, Harpp DN, Kanara I, Mavrakis AN, Pernokas J, Pernokas M, Pinkert CA, Powers WR, Sampani K, Steliou K, Vavvas DG, Zamboni RJ, Kodukula K, Chen X. Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs. Biores Open Access. 2020; 9(1):94-105. PMID: 32257625
     
  4. Faessel HM, Mould DR, Zhou X, Faller DV, Sedarati F, Venkatakrishnan K. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. Br J Clin Pharmacol. 2019 11; 85(11):2568-2579. PMID: 31355467
     
  5. Bell JA, Galaznik A, Pompilus F, Strzok S, Bejar R, Scipione F, Fram RJ, Faller DV, Cano S, Marquis P. A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Patient Rep Outcomes. 2019 Jun 19; 3(1):35. PMID: 31218454
     
  6. Bell JA, Galaznik A, Blazer M, Shih HC, Farrelly E, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV. Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States. Pharmacoecon Open. 2019 Jun; 3(2):237-245. PMID: 30324565
     
  7. Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. Br J Clin Pharmacol. 2019 07; 85(7):1464-1473. PMID: 30845347
     
  8. Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota VK. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent. Leuk Res. 2019 03; 78:45-51. PMID: 30716655
     
  9. Faller DV. Response to "Selective PKCd Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms". ACS Chem Biol. 2019 01 18; 14(1):131. PMID: 30525445
     
  10. Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K. A New Approach to Treating Neurodegenerative Otologic Disorders. Biores Open Access. 2018; 7(1):107-115. PMID: 30069423
     
Showing 10 of 290 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 268 publications over 38 distinct years, with a maximum of 16 publications in 1988 and 1995

YearPublications
19831
19842
19855
19867
198715
198816
19896
19909
19919
19923
19935
199410
199516
199613
199710
19987
19999
20007
20017
20029
20034
20042
20055
200612
20076
20089
20099
20104
20117
20125
20134
20146
20154
20165
20173
20189
20195
20203

Contact for Mentoring:

72 E. Concord St Silvio Conte (K)
Boston MA 02118
Google Map


Faller's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department